NCT05431504View on ClinicalTrials.gov

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Advanced Breast Cancer
Interventions
DRUG

Dalpiciclib in combination with endocrine therapy by Physicians choice

"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT05431504 - The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | Biotech Hunter | Biotech Hunter